Dr. Tan studies transcriptional regulation during normal development and disease. This involves the interplay of multiple transcription and epigenetic factors in a 3D chromosomal environment. Using experimental genomics and computational modeling, Dr. Tan investigates transcriptional regulatory networks underlying embryonic hematopoiesis, T cell differentiation, and pediatric leukemia.
Dr. Xing is the Francis West Lewis Chair and director of the Center for Computational and Genomic Medicine at CHOP, and professor of Pathology and Laboratory Medicine at the University of Pennsylvania. His research focuses on computational biology and genomics of RNA processing and regulation.
Dr. Diskin's research is focused on translational genomics in childhood cancers. Her laboratory seeks to identify the genetic basis of childhood cancers by combining quantitative computational methods with rigorous "wet-lab" experimental approaches. In parallel, she has developed, and is applying, a proteogenomic approach to identify novel immunotherapeutic targets for high-risk and relapsed pediatric malignancies.
Dr. Alexander-Bloch investigates normal brain development and the altered developmental trajectories that lead to mental illness. His multi-disciplinary research integrates brain imaging, genomics and clinical information.
Dr. Wang's research focuses on the development of bioinformatics methods to improve the understanding of the genetic basis of human diseases, and the integration of electronic health records and genomic information to facilitate genomic medicine on scale.
Dr. Parish-Morris investigates social communication, specifically how vocal communication develops in children and adolescents with autism spectrum disorder. She uses computational approaches and machine learning to identify objective and reliable behavioral markers for use in screening, treatment and intervention response tracking, and to advance biological research.
Dr. Shalem’s research focuses on translational target discovery for a range of neurodegenerative diseases. He combines technology development of large-scale CRISPR-based perturbation screens with application of such technology together with additional genomic approaches.